Pressure BioSciences, Inc. (PBIO)


0.00 (0.00%)
Symbol PBIO
Price $1.19
Beta 0.695
Volume Avg. 0.01M
Market Cap 13.171M
Shares () -
52 Week Range 0.91-2.46
1y Target Est -
DCF Unlevered PBIO DCF ->
DCF Levered PBIO LDCF ->
ROE 61.30% Strong Buy
ROA -560.87% Strong Sell
Operating Margin -
Debt / Equity -109.54% Sell
P/E -0.46 Neutral
P/B -0.44 Neutral


Consensus EPS

Upgrades & Downgrades

Latest PBIO news

Mr. Richard T. Schumacher
Medical Devices
Other OTC

Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the North America, Europe, and Asia. The company's pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. It offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and The Shredder SG3. The company also distributes cell disruption equipment, parts, and consumables. In addition, it offers Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, PCT-Micro Pestle, and pressure used to lyse samples for extraction tubes, as well as application specific kits, including consumable products and reagents. The company serves researchers at academic laboratories, government agencies, biotechnology companies, pharmaceutical firms, and other life science institutions. It has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; Steinbeis Centre for biopolymer analysis and biological mass spectrometry; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. Pressure BioSciences, Inc. was incorporated in 1978 and is based in South Easton, Massachusetts. As of August 2, 2022, Pressure BioSciences, Inc. operates as a subsidiary of Emergent Health Corp.